scholarly journals Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification

2012 ◽  
Vol 106 (5) ◽  
pp. 916-922 ◽  
Author(s):  
A S Betof ◽  
Z N Rabbani ◽  
M E Hardee ◽  
S J Kim ◽  
G Broadwater ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Carbonic Anhydrase ◽  
Early Stage ◽  
Predictive Marker ◽  
Carbonic Anhydrase Ix ◽  
Early Stage Breast Cancer ◽  
Doxorubicin Resistance ◽  
Top2a Amplification

scholarly journals Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Zsuzsanna Varga ◽  
Qiyu Li ◽  
Wolfram Jochum ◽  
Ulrike Perriard ◽  
Tilman Rau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Confidence Interval ◽  
Predictive Value ◽  
Early Stage ◽  
Accurate Determination ◽  
Predictive Marker ◽  
Early Stage Breast Cancer ◽  
Pilot Phase ◽  
Ki 67 ◽  
Exact Counting

Abstract The assessment of Ki-67 in early-stage breast cancer has become an important diagnostic tool in planning adjuvant therapy, particularly for the administration of additional chemotherapy to hormone-responsive patients. An accurate determination of the Ki-67 index is of the utmost importance; however, the reproducibility is currently unsatisfactory. In this study, we addressed the predictive/prognostic value of Ki-67 index assessed by using the most reproducible methods, which were identified in the pilot phase. Paraffin blocks obtained from patients with moderately differentiated, estrogen receptor (ER)-positive early-stage breast cancer in Switzerland, who were originally randomized to the treatment arms with and without chemotherapy in the IBCSG VIII-IX trials, were retrieved. Of these 344 randomized patients, we identified 158 patients (82 treated with and 76 treated without chemotherapy) for whom sufficient tumour tissue was available. The presence of Ki-67 was assessed visually by counting 2000 cells at the periphery (A) and estimating the number of positive cells in five different peripheral regions (C), which was determined to be the most reproducible method identified the pilot phase. The prognostic and predictive value was assessed by calculating the breast cancer-free interval (BCFI) and overall survival (OS) rate. Ki-67 was considered a numerical and categorical variable when different cut-off values were used (10%, 14%, 20% and 30%). An mRNA-based subtyping by using the MammaTyper kit with the application of a 20% Ki-67 immunohistochemistry (IHC) cut-off equivalent was also performed. 158 of 344 randomized patients could be included in the Ki-67 analysis. The mean Ki-67 values obtained by using the two methods differed (A: 21.32% and C: 16.07%). Ki-67 assessed by using method A with a cut-off of 10% was a predictive marker for OS, as the hazard ratio (>10% vs. <=10%) in patients with chemotherapy was 0.48 with a 95% confidence interval of [0.19–1.19]. Further, the HR of patients treated without chemotherapy was 3.72 with a 95% confidence interval of [1.16–11.96] (pinteraction=0.007). Higher Ki-67 index was not associated with outcome and using the 10% Ki-67 cut-off there was an opposite association for patients with and without chemotherapy. Ki-67 assessments with IHC significantly correlated with MammaTyper results (p=0.002). The exact counting method (A) performed via a light-microscope revealed the predictive value of Ki-67 assessment with a 10% cut-off value. Further analyses employing image analyses and/or mRNA-based-assessments in larger populations are warranted.

scholarly journals Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer and Evaluation of βIII‐Tubulin Expression as a Predictive Marker

2013 ◽  
Vol 18 (7) ◽  
pp. 787-794 ◽  
Author(s):  
Cristina Saura ◽  
Ling‐Ming Tseng ◽  
Stephen Chan ◽  
Raju T. Chacko ◽  
Mario Campone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Predictive Marker ◽  
Early Stage Breast Cancer

Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 11505-11505 ◽  
Author(s):  
Janning Melanie ◽  
Volkmar Müller ◽  
Eik Vettorazzi ◽  
Miguel Cubas-Cordova ◽  
Christine Eulenburg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Carbonic Anhydrase ◽  
Predictive Marker ◽  
Carbonic Anhydrase Ix ◽  
Phase Iii ◽  
Cancer Trial ◽  
Biomarker Analysis

Mastectomy trends for early-stage breast cancer: a single-center experience

2020 ◽  
Vol 1 (50) ◽  
pp. 9
Author(s):  
Cristian Lungulescu ◽  
Mihaela Dănciulescu ◽  
Denisa Bărbulescu ◽  
Ana Dorobanţu ◽  
Georgiana Camen
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Single Center ◽  
Single Center Experience
Sign in / Sign up

Export Citation Format

Share Document